Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant AR Inhibition With or Without SRC or MEK Inhibition in Prostate Cancer
NCT01990196Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2014
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib, dasatinib in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Sep 2014; status: active, not recruiting.
02
Drugs
trametinibdasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01990196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01990196.